BR112017008165B8 - anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado - Google Patents

anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado

Info

Publication number
BR112017008165B8
BR112017008165B8 BR112017008165A BR112017008165A BR112017008165B8 BR 112017008165 B8 BR112017008165 B8 BR 112017008165B8 BR 112017008165 A BR112017008165 A BR 112017008165A BR 112017008165 A BR112017008165 A BR 112017008165A BR 112017008165 B8 BR112017008165 B8 BR 112017008165B8
Authority
BR
Brazil
Prior art keywords
antibody
isolated polypeptide
intracellular component
sdabs
directed against
Prior art date
Application number
BR112017008165A
Other languages
English (en)
Other versions
BR112017008165B1 (pt
BR112017008165A2 (pt
Inventor
Singh Sunanda
Original Assignee
Singh Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singh Biotechnology Llc filed Critical Singh Biotechnology Llc
Priority to BR122020006907A priority Critical patent/BR122020006907B8/pt
Priority to BR122020006914A priority patent/BR122020006914B8/pt
Priority to BR122020006918A priority patent/BR122020006918B8/pt
Publication of BR112017008165A2 publication Critical patent/BR112017008165A2/pt
Publication of BR112017008165B1 publication Critical patent/BR112017008165B1/pt
Publication of BR112017008165B8 publication Critical patent/BR112017008165B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção fornece composições e métodos para tratar uma condição ou uma doença sem o uso de sequências de direcionamento exógenas ou composições químicas. a presente invenção refere-se a anticorpos de domínio único (sdabs), proteínas e polipeptídeos compreendendo os sdabs que são direcionados contra componentes intracelulares que causam uma condição ou doença. a invenção também inclui ácidos nucleicos que codificam os sdabs, proteínas e polipeptídeos, e composições compreendendo os sdabs. a invenção inclui o uso das composições, sdabs, e ácidos nucleicos que codificam os sdabs para fins profiláticos, terapêuticos ou de diagnóstico.
BR112017008165A 2014-10-23 2015-10-23 anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado BR112017008165B8 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR122020006907A BR122020006907B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR122020006914A BR122020006914B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR122020006918A BR122020006918B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US62/067,908 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US62/148,656 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US62/188,353 2015-07-02
US201562210795P 2015-08-27 2015-08-27
US62/210,795 2015-08-27
PCT/US2015/057223 WO2016065323A2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens

Publications (3)

Publication Number Publication Date
BR112017008165A2 BR112017008165A2 (pt) 2018-03-06
BR112017008165B1 BR112017008165B1 (pt) 2020-04-22
BR112017008165B8 true BR112017008165B8 (pt) 2020-10-27

Family

ID=55761757

Family Applications (4)

Application Number Title Priority Date Filing Date
BR122020006907A BR122020006907B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR122020006914A BR122020006914B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112017008165A BR112017008165B8 (pt) 2014-10-23 2015-10-23 anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR122020006918A BR122020006918B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122020006907A BR122020006907B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR122020006914A BR122020006914B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020006918A BR122020006918B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado

Country Status (23)

Country Link
US (4) US9695234B2 (pt)
EP (3) EP4006052A1 (pt)
JP (5) JP2017538671A (pt)
KR (4) KR102023289B1 (pt)
CN (2) CN106852148B (pt)
AU (4) AU2015335600B2 (pt)
BR (4) BR122020006907B8 (pt)
CA (3) CA3052777C (pt)
CY (2) CY1122035T1 (pt)
DK (2) DK3209685T3 (pt)
ES (2) ES2900253T3 (pt)
HR (2) HRP20211889T1 (pt)
HU (2) HUE057605T2 (pt)
IL (2) IL289769B1 (pt)
LT (2) LT3590962T (pt)
MX (2) MX2017003268A (pt)
PL (2) PL3209685T3 (pt)
PT (2) PT3590962T (pt)
RS (2) RS62694B1 (pt)
RU (1) RU2017116710A (pt)
SI (2) SI3209685T1 (pt)
TW (1) TWI664289B (pt)
WO (1) WO2016065323A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
LT3590962T (lt) 2014-10-23 2021-12-27 Singh Molecular Medicine, Llc Vieno domeno antikūnai, nukreipti prieš viduląstelinius antigenus
US20170267784A1 (en) * 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
BR112017020275A8 (pt) 2015-03-31 2023-01-31 Sorriso Pharmaceuticals Inc Polipeptídeos
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN112274649A (zh) * 2015-12-10 2021-01-29 希望之城 细胞穿透花青偶联抗体
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
WO2019125033A1 (ko) * 2017-12-22 2019-06-27 (주)로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물
JP2021523115A (ja) * 2018-05-04 2021-09-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症性疾患または障害を治療するための方法および組成物
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114466864A (zh) 2019-06-21 2022-05-10 索瑞索制药公司 多肽
MX2021015763A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
CA3171066A1 (en) 2020-03-11 2021-09-16 Saar GILL Methods and composition for gene delivery using an engineered viral particle
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939A (zh) * 2021-04-14 2022-10-21 中山大学 一种融合蛋白及其制备方法与应用
WO2023283381A1 (en) * 2021-07-07 2023-01-12 Singh Biotechnology, Llc Suppression of uveitis by single domain antibody
US20240101652A1 (en) * 2021-08-27 2024-03-28 Singh Biotechnology, Llc Therapeutic single domain antibody
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
EP1204674A4 (en) 1999-07-27 2005-06-01 Abgenix Inc METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040052762A1 (en) 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
IL156690A0 (en) * 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
CA2504818C (en) * 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20100143371A1 (en) 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2010001325A2 (en) * 2008-06-30 2010-01-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
EP2794661B1 (en) * 2011-12-20 2019-03-06 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
BR112015009559A2 (pt) * 2012-10-31 2017-11-14 Isis Pharmaceuticals Inc uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
AU2014227824B2 (en) * 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
EP2975936A4 (en) * 2013-03-22 2017-03-15 University of Hawaii Novel stat3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
JP6736464B2 (ja) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
LT3590962T (lt) 2014-10-23 2021-12-27 Singh Molecular Medicine, Llc Vieno domeno antikūnai, nukreipti prieš viduląstelinius antigenus

Also Published As

Publication number Publication date
KR102207381B1 (ko) 2021-01-27
HUE047601T2 (hu) 2020-05-28
AU2021200416B2 (en) 2022-06-09
CY1122035T1 (el) 2020-10-14
JP6986180B2 (ja) 2021-12-22
US9663570B2 (en) 2017-05-30
LT3209685T (lt) 2019-08-26
DK3590962T3 (da) 2021-12-13
KR102023289B1 (ko) 2019-09-19
WO2016065323A2 (en) 2016-04-28
MX2021001098A (es) 2021-03-31
LT3590962T (lt) 2021-12-27
CY1124867T1 (el) 2022-11-25
BR122020006914B8 (pt) 2023-01-31
JP2022037002A (ja) 2022-03-08
EP3590962A1 (en) 2020-01-08
SI3590962T1 (sl) 2022-02-28
EP3209685A4 (en) 2018-01-24
RS59063B1 (sr) 2019-08-30
US20160115248A1 (en) 2016-04-28
WO2016065323A3 (en) 2016-06-16
CN111848793A (zh) 2020-10-30
CA2962275A1 (en) 2016-04-28
JP7195400B2 (ja) 2022-12-23
EP3209685A2 (en) 2017-08-30
BR122020006918B1 (pt) 2022-03-15
ES2731876T3 (es) 2019-11-19
HUE057605T2 (hu) 2022-06-28
US9546211B2 (en) 2017-01-17
US20160115244A1 (en) 2016-04-28
KR20190107199A (ko) 2019-09-18
JP2020015732A (ja) 2020-01-30
ES2900253T3 (es) 2022-03-16
RS62694B1 (sr) 2022-01-31
DK3209685T3 (da) 2019-07-29
HRP20211889T1 (hr) 2022-03-04
EP3209685B1 (en) 2019-04-24
PT3590962T (pt) 2021-12-15
AU2019204614B2 (en) 2020-10-22
AU2022204167A1 (en) 2022-06-30
US20160115226A1 (en) 2016-04-28
CA3052777C (en) 2021-06-01
EP4006052A1 (en) 2022-06-01
KR20190108646A (ko) 2019-09-24
KR20170070002A (ko) 2017-06-21
CA3052777A1 (en) 2016-04-28
TWI664289B (zh) 2019-07-01
IL250961A0 (en) 2017-04-30
PL3209685T3 (pl) 2020-01-31
IL250961B (en) 2022-02-01
US9695234B2 (en) 2017-07-04
BR112017008165B1 (pt) 2020-04-22
JP2021165278A (ja) 2021-10-14
CA2962275C (en) 2019-11-05
EP3590962B1 (en) 2021-09-29
JP2017538671A (ja) 2017-12-28
JP6670963B2 (ja) 2020-03-25
CN106852148A (zh) 2017-06-13
AU2021200416A1 (en) 2021-02-25
JP2019142885A (ja) 2019-08-29
BR122020006914B1 (pt) 2022-03-22
RU2017116710A (ru) 2018-11-23
AU2015335600B2 (en) 2019-04-04
IL289769B1 (en) 2024-01-01
KR101831123B1 (ko) 2018-02-22
CN111848793B (zh) 2023-08-18
PT3209685T (pt) 2019-06-27
BR122020006907B8 (pt) 2023-01-31
CA3114318A1 (en) 2016-04-28
US20160115247A1 (en) 2016-04-28
IL289769A (en) 2022-03-01
MX2017003268A (es) 2017-08-02
KR102207382B1 (ko) 2021-01-27
SI3209685T1 (sl) 2019-10-30
BR122020006918B8 (pt) 2023-01-31
BR112017008165A2 (pt) 2018-03-06
KR20180021205A (ko) 2018-02-28
AU2019204614A1 (en) 2019-07-18
CN106852148B (zh) 2020-07-31
HRP20191056T1 (hr) 2019-09-20
JP6928773B2 (ja) 2021-09-01
AU2015335600A1 (en) 2017-03-16
PL3590962T3 (pl) 2022-01-31
BR122020006907B1 (pt) 2022-03-22
TW201615834A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CU20160101A7 (es) Inmunoglobulina con fab en tándem
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
AR101669A1 (es) Constructos de anticuerpos para cdh19 y cd3
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
BR112018008840A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2572 DE 22.04.2020, QUANTO AO TITULO

B25G Requested change of headquarter approved

Owner name: SINGH BIOTECHNOLOGY, LLC (US)

B25A Requested transfer of rights approved

Owner name: SINGH MOLECULAR MEDICINE, LLC (US)

B25G Requested change of headquarter approved

Owner name: SINGH MOLECULAR MEDICINE, LLC (US)